Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Apixaban Versus Dalteparin for Thromboprophylaxis...
Conference

Apixaban Versus Dalteparin for Thromboprophylaxis in Patients with Acute Spinal Cord Injury: A Pilot Study

Abstract

Background: Patients with acute spinal cord injury (SCI) have a high risk of venous thromboembolism despite thromboprophylaxis. Low molecular weight heparin (LMWH), the current standard of care, is inconvenient for long term thromboprophylaxis, costly, and partially effective. Direct oral anticoagulants (DOACs) have been shown to be at least as effective and as safe as LMWH in other thromboprophylaxis settings but there is no randomized …

Authors

Piran S; Zondag M; Bednar D; Drew B; Chmiel A; Chan N; Eikelboom JW; Schulman S

Volume

134

Publisher

American Society of Hematology

Publication Date

November 13, 2019

DOI

10.1182/blood-2019-124601

Conference proceedings

Blood

Issue

Supplement_1

ISSN

0006-4971